Revolution Medicines(DE:42Z)
€146.25-1.25 (-0.85%)
DE:42Z
Revolution Medicines financials statements
€146.25
At close:-1.25 (-0.85%)
Revolution Medicines (42Z) Ratios
17 Followers
Revolution Medicines Ratios
DE:42Z's free cash flow for Q3 2026 was $-419.35M. For the 2026 fiscal year, DE:42Z's free cash flow was decreased by $-3.70M and operating cash flow was $-415.65M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 7.14 | 14.20 | 13.06 | 10.65 | 9.77 |
| Quick Ratio | 7.14 | 14.20 | 13.06 | 10.65 | 9.77 |
| Cash Ratio | 1.32 | 3.31 | 4.84 | 2.60 | 1.80 |
| Solvency Ratio | -1.54 | -2.01 | -1.81 | -1.89 | -1.33 |
| Operating Cash Flow Ratio | -3.09 | -3.40 | -2.44 | -3.62 | -2.44 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 1.35B | $ 2.03B | $ 1.64B | $ 533.44M | $ 454.35M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.07 | 0.05 | 0.04 | 0.08 | 0.09 |
| Debt-to-Equity Ratio | 0.10 | 0.06 | 0.05 | 0.09 | 0.11 |
| Debt-to-Capital Ratio | 0.09 | 0.06 | 0.05 | 0.09 | 0.10 |
| Long-Term Debt-to-Capital Ratio | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.44 | 1.13 | 1.13 | 1.18 | 1.22 |
| Debt Service Coverage Ratio | -45.00 | 0.00 | -1565.52 | 0.00 | -14978.92 |
| Interest Coverage Ratio | -48.80 | 0.00 | -1607.87 | 0.00 | -15667.33 |
| Debt to Market Cap | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.96 | 0.81 | 0.78 | 0.80 | 0.92 |
| Net Debt to EBITDA | 0.21 | 0.69 | 1.27 | 0.39 | 0.23 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | 0.00% | 0.00% | -4207.12% | -730.01% | -636.54% |
| EBITDA Margin | 0.00% | 0.00% | -4126.74% | -702.72% | -611.59% |
| Operating Profit Margin | 0.00% | 0.00% | -4207.12% | -730.01% | -639.70% |
| Pretax Profit Margin | 0.00% | 0.00% | -3798.71% | -704.14% | -636.58% |
| Net Profit Margin | 0.00% | 0.00% | -3768.28% | -702.95% | -636.58% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -3768.28% | -702.95% | -636.58% |
| Net Income Per EBT | 100.00% | 99.87% | 99.20% | 99.83% | 100.00% |
| EBT Per EBIT | 95.68% | 87.14% | 90.29% | 96.46% | 99.51% |
| Return on Assets (ROA) | -48.05% | -23.46% | -21.17% | -30.63% | -25.35% |
| Return on Equity (ROE) | -69.35% | -26.49% | -23.89% | -36.30% | -31.05% |
| Return on Capital Employed (ROCE) | -57.28% | -28.80% | -25.40% | -34.44% | -27.74% |
| Return on Invested Capital (ROIC) | -56.83% | -28.61% | -25.10% | -34.07% | -27.49% |
| Return on Tangible Assets | -49.53% | -24.13% | -21.94% | -33.68% | -28.20% |
| Earnings Yield | -7.47% | -8.18% | -13.45% | -12.95% | -10.21% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 9.23 | 7.57 | 4.96 |
| Payables Turnover | 0.26 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.12 | 0.48 | 0.41 |
| Asset Turnover | 0.00 | 0.00 | 0.01 | 0.04 | 0.04 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.01 | 0.06 | 0.06 |
| Cash Conversion Cycle | -1424.38 | 0.00 | 39.53 | 48.21 | 73.63 |
| Days of Sales Outstanding | 0.00 | 0.00 | 39.53 | 48.21 | 73.63 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1424.38 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 39.53 | 48.21 | 73.63 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -4.72 | -3.32 | -3.10 | -2.78 | -2.02 |
| Free Cash Flow Per Share | -4.81 | -3.38 | -3.17 | -2.92 | -2.11 |
| Dividend Paid and CapEx Coverage Ratio | -56.14 | -54.08 | -45.36 | -20.75 | -22.55 |
| Capital Expenditure Coverage Ratio | -56.14 | -54.08 | -45.36 | -20.75 | -22.55 |
| Operating Cash Flow Coverage Ratio | -5.66 | -4.10 | -3.99 | -3.50 | -2.21 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -30.27 | -6.34 | -5.01 |
| Free Cash Flow Yield | -6.03% | -7.74% | -11.04% | -12.25% | -8.39% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -13.39 | -12.22 | -7.44 | -7.72 | -9.79 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 280.24 | 54.28 | 62.35 |
| Price-to-Book (P/B) Ratio | 9.28 | 3.24 | 1.78 | 2.80 | 3.04 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -16.57 | -12.92 | -9.06 | -8.16 | -11.92 |
| Price-to-Operating Cash Flow Ratio | -16.87 | -13.16 | -9.26 | -8.56 | -12.45 |
| Price-to-Earnings Growth (PEG) Ratio | -0.20 | 1.68 | -0.29 | -0.31 | -0.19 |
| Enterprise Value Multiple | -13.68 | -11.76 | -5.52 | -7.33 | -9.96 |
| Enterprise Value | 14.92B | 6.93B | 2.64B | 1.82B | 1.79B |
| EV to EBITDA | -13.68 | -11.76 | -5.52 | -7.33 | -9.96 |
| EV to Sales | 0.00 | 0.00 | 227.71 | 51.54 | 60.93 |
| EV to Free Cash Flow | -16.33 | -12.21 | -7.36 | -7.75 | -11.65 |
| EV to Operating Cash Flow | -16.62 | -12.43 | -7.52 | -8.13 | -12.17 |
| Tangible Book Value Per Share | 8.21 | 13.08 | 15.50 | 7.59 | 7.25 |
| Shareholders’ Equity Per Share | 8.58 | 13.50 | 16.14 | 8.50 | 8.28 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.10 | 0.44 | 0.40 |
| Net Income Per Share | -5.95 | -3.58 | -3.86 | -3.08 | -2.57 |
| Tax Burden | 1.00 | 1.00 | 0.99 | 1.00 | 1.00 |
| Interest Burden | 1.02 | 1.00 | 0.90 | 0.96 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 36.54 | 7.15 | 6.36 |
| SG&A to Revenue | 0.00 | 0.00 | 6.53 | 1.15 | 1.04 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 5.33 | 0.88 | 0.71 |
| Income Quality | 0.79 | 0.93 | 0.80 | 0.90 | 0.79 |
Currency in USD

